EP Patent

EP3542792A1 — Controlled release 25-hydroxyvitamin d

Assigned to Eirgen Pharma Ltd · Expires 2019-09-25 · 7y expired

What this patent protects

The invention provides a pharmaceutical composition comprising an oral formulation of 25-hydroxyvitamin Dfor use in a method of treatment of secondary hyperparathyroidism in a human patient having chronic kidney disease. The method of treatment comprises administering the composi…

USPTO Abstract

The invention provides a pharmaceutical composition comprising an oral formulation of 25-hydroxyvitamin Dfor use in a method of treatment of secondary hyperparathyroidism in a human patient having chronic kidney disease. The method of treatment comprises administering the composition to the patient and the patient is treated without causing supraphysiological surges in blood levels of 25-hydroxyvitamin D.

Drugs covered by this patent

Patent Metadata

Patent number
EP3542792A1
Jurisdiction
EP
Classification
—
Expires
2019-09-25
Drug substance claim
No
Drug product claim
No
Assignee
Eirgen Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.